Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB. Key Therapeutic Areas • Oncology • Auto-immune Disorders Portfolio • Novel PAD4 inhibitors targeting auto-immune disorders • Dual LSD1/HDAC6 inhibitors targeting cancer • Novel small molecule PD-L1 inhibitors • Novel brain penetrating PRMT5 inhibitors targeting cancer